Clinical Trial Update: Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating the combination of Actimab-A and cemiplimab (REGN2810) for recurrent glioblastoma, with the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Idh-wildtype
• Glioma Who
• Gliosarcoma

Drugs mentioned

• Actimab-A
• Cemiplimab (cemiplimab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Status: NOT_YET_RECRUITING